Literature DB >> 11925306

Metformin for weight loss in pediatric patients taking psychotropic drugs.

John A Morrison1, Elizabeth M Cottingham, Bruce A Barton.   

Abstract

OBJECTIVE: Metformin was assessed as a treatment for weight gain in children taking olanzapine, risperidone, quetiapine, or valproate.
METHOD: The subjects were 19 patients aged 10-18 years; 15 were white and four were black, and there were 12 boys and seven girls. In a 12-week open-label study, each patient received metformin, 500 mg t.i.d. Changes in weight and body mass index were evaluated by using repeated measures analysis of variance.
RESULTS: Of the 19 patients, 15 lost weight, three gained 1.6 kg or less, and one had no change. The mean changes in weight and body mass index at 12 weeks were highly significant.
CONCLUSIONS: Metformin merits further study as a treatment for weight gain in patients taking psychotropic medications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11925306     DOI: 10.1176/appi.ajp.159.4.655

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  37 in total

1.  A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.

Authors:  Benjamin U Nwosu; Bruce Meltzer; Louise Maranda; Carol Ciccarelli; Daniel Reynolds; Laura Curtis; Jean King; Jean A Frazier; Mary M Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

Review 2.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Psychotropic-induced weight gain and potential pharmacologic treatment strategies.

Authors:  Barbara L Gracious; Ashley E Meyer
Journal:  Psychiatry (Edgmont)       Date:  2005-01

Review 4.  Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.

Authors:  Samir Kumar Praharaj; Amlan Kusum Jana; Nishant Goyal; Vinod Kumar Sinha
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 5.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 6.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

7.  [Not Available].

Authors:  Josephine Ho; Constadina Panagiotopoulos; Brian McCrindle; Silviu Grisaru; Tamara Pringsheim
Journal:  Paediatr Child Health       Date:  2012-10       Impact factor: 2.253

8.  Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

Authors:  David C Henderson; Xiaoduo Fan; Paul M Copeland; Bikash Sharma; Christina P Borba; Ryan Boxill; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff
Journal:  J Clin Psychopharmacol       Date:  2009-04       Impact factor: 3.153

Review 9.  Metformin: new understandings, new uses.

Authors:  Ripudaman S Hundal; Silvio E Inzucchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Authors:  D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.